Study on Safety and Efficacy of the Recombinant Factor VIII of Saman daroo 8 Pharmaceutical Company (Safacto) in Comparing with Recombinant Factor VIII of Pfizer Pharmaceutical Company (Xyntha) in Patients with Sever Hemophilia A,Exposing to Factor VIII for More Than 50 Days

Trial Profile

Study on Safety and Efficacy of the Recombinant Factor VIII of Saman daroo 8 Pharmaceutical Company (Safacto) in Comparing with Recombinant Factor VIII of Pfizer Pharmaceutical Company (Xyntha) in Patients with Sever Hemophilia A,Exposing to Factor VIII for More Than 50 Days

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Recombinant-factor-VIII-Saman-Daroo-8 (Primary) ; Moroctocog alfa
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Sponsors Saman daroo 8
  • Most Recent Events

    • 06 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top